The role of brachytherapy in the treatment of glioblastoma multiforme

被引:46
作者
Barbarite, Eric [1 ]
Sick, Justin T. [2 ]
Berchmans, Emmanuel [1 ]
Bregy, Amade [1 ]
Shah, Ashish H. [1 ]
Elsayyad, Nagy [3 ]
Komotar, Ricardo J. [1 ]
机构
[1] Univ Miami Miller, Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace,2nd Floor, Miami, FL 33136 USA
[2] Univ Miami Miller, Sch Med, Miami Project Cure Paralysis, Miami, FL USA
[3] Univ Miami Miller, Sch Med, Dept Radiat Oncol, Miami, FL USA
关键词
Glioblastoma; Brachytherapy; Outcomes; Side effects; Systematic analysis; CEREBRAL RADIATION NECROSIS; NEWLY-DIAGNOSED GLIOBLASTOMA; RECURRENT MALIGNANT GLIOMAS; DOSE-RATE BRACHYTHERAPY; GLIASITE BRACHYTHERAPY; I-125; BRACHYTHERAPY; INTERSTITIAL BRACHYTHERAPY; INITIAL TREATMENT; TUMOR RECURRENCE; BRAIN-TUMORS;
D O I
10.1007/s10143-016-0727-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Brachytherapy (BT) for glioblastoma multiforme (GBM) involves the use of radioactive isotopes to deliver ionizing radiation directly into the tumor bed. Its application as a means to prolong survival in GBM patients over the past few decades has come with variable success. The objective of this review is to describe the utility of BT in GBM, and to report the outcomes and adverse events associated with its use in different multimodal treatment approaches. A search of the literature was conducted using the PubMed database. The most recent search was performed in September 2015. Thirty-two series involving 1571 patients were included in our review. The longest median overall survival (MOS) following BT for newly diagnosed GBM reached 28.5 months. Overall, 1-, 2-, and 3-year survival rates were 46-89 %, 20-57 %, and 14-27 %. For recurrent GBM, the longest reported MOS after BT was 15.9 months. One-, 2-and 3-year survival rates for recurrent GBM were 10-66 %, 3-23 %, and 9-15 %. Adverse events were reported in 27 % of patients. Reoperation for radiation necrosis occurred in 4 and 27 % of patients following low- and high-dose rate BT, respectively. BT is a feasible option for extending survival in carefully selected GBM patients. As patient outcomes and overall survival improve with more aggressive radiotherapy, so does the risk of radiation-related complications. The most effective use of BT is likely as a part of multimodal treatment with other novel therapies.
引用
收藏
页码:195 / 211
页数:17
相关论文
共 58 条
[1]   Systemic iodine 125 activity after GliaSite brachytherapy: Safety considerations [J].
Adkison, Jarrod B. ;
Thomadsen, Bruce ;
Howard, Steven P. .
BRACHYTHERAPY, 2008, 7 (01) :43-46
[2]   Combined salvage therapies for recurrent glioblastoma multiforme: evaluation of an interdisciplinary treatment algorithm [J].
Archavlis, Eleftherios ;
Tselis, Nikolaos ;
Birn, Gerhard ;
Ulrich, Peter ;
Zamboglou, Nikolaos .
JOURNAL OF NEURO-ONCOLOGY, 2014, 119 (02) :387-395
[3]   Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme [J].
Archavlis, Eleftherios ;
Tselis, Nikolaos ;
Birn, Gerhard ;
Ulrich, Peter ;
Baltas, Dimos ;
Zamboglou, Nikolaos .
BMJ OPEN, 2013, 3 (03)
[4]   Treatment of recurrent glioblastoma multiforme with gliasite brachytherapy [J].
Chan, TA ;
Weingart, JD ;
Parisi, M ;
Hughes, MA ;
Olivi, A ;
Borzillary, S ;
Alahakone, D ;
Detorie, NA ;
Wharam, MD ;
Kleinberg, L .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (04) :1133-1139
[5]   High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes [J].
Chang, CN ;
Chen, WC ;
Wei, KC ;
Ng, SH ;
Ho, YS ;
Huang, DYC ;
Lee, SPH ;
Hong, JH .
JOURNAL OF NEURO-ONCOLOGY, 2003, 61 (01) :45-55
[6]   Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme [J].
Chen, Allen M. ;
Chang, Susan ;
Pouliot, Jean ;
Sneed, Penny K. ;
Prados, Michael D. ;
Lamborn, Kathleen R. ;
Malec, Mary K. ;
McDermott, Michael W. ;
Berger, Mitchell S. ;
Larson, David A. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03) :825-830
[7]   Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliaSite® Radiation Therapy System [J].
Chino, Kazumi ;
Silvain, Daniel ;
Grace, Ana ;
Stubbs, James ;
Stea, Baldassarre .
MEDICAL PHYSICS, 2008, 35 (07) :3383-3388
[8]  
Commission USNR, 2008, CONS GUID MAT LIC PR
[9]   Neurologic complications of radiation therapy [J].
Cross, NE ;
Glantz, MJ .
NEUROLOGIC CLINICS, 2003, 21 (01) :249-+
[10]   Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme [J].
Darakchiev, Borimir J. ;
Albright, Robert E. ;
Breneman, John C. ;
Warnick, Ronald E. .
JOURNAL OF NEUROSURGERY, 2008, 108 (02) :236-242